Dyslipidaemia - Current and Future Treatment Paradigm

Abstract

Dyslipidaemia is one of the major risk factors for coronary vascular disorders. Dyslipidaemia prevention and management can have a great impact on cardiovascular morbidity and mortality. There are many lipid-modifying pharmacological medicines on the market, and more are being developed. New guidelines recommend aggressive lipid-lowering targets depending on the atherosclerotic cardiovascular (ASCVD) risk. Depending on the risk of these risks, new guidelines advocate aggressive lipidlowering targets. For many years, statins had been the standard care, and demonstrated to reduce the risk of cardiovascular events. Novel molecules such as PCSK9 inhibitors, selective inhibitors of microsomal triglyceride transfer protein, small interfering RNA (siRNA), and antisense oligonucleotide drugs, could be interesting new additions to effective lipid-lowering therapy, are now accessible. We look into the history, method of action, key clinical studies, and side effects of therapeutic targets for dyslipidaemia to see where they fit into the therapy armamentarium now and in the future.